BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36522168)

  • 1. Redistribution of lamina-associated domains reshapes binding of pioneer factor FOXA2 in development of nonalcoholic fatty liver disease.
    Wei X; Murphy MA; Reddy NA; Hao Y; Eggertsen TG; Saucerman JJ; Bochkis IM
    Genome Res; 2022; 32(11-12):1981-1992. PubMed ID: 36522168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes at the nuclear lamina alter binding of pioneer factor Foxa2 in aged liver.
    Whitton H; Singh LN; Patrick MA; Price AJ; Osorio FG; López-Otín C; Bochkis IM
    Aging Cell; 2018 Jun; 17(3):e12742. PubMed ID: 29484800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Foxa2 attenuates steatosis and inhibits the NF-κB/IKK signaling pathway in nonalcoholic fatty liver disease.
    Yang L; Ma Q; Chen J; Kong X; Yu X; Wang W
    PeerJ; 2023; 11():e16466. PubMed ID: 38084145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipramine activates FAM3A-FOXA2-CPT2 pathway to ameliorate hepatic steatosis.
    Liu X; Hou S; Xiang R; Hu C; Chen Z; Li N; Yan H; Yu X; Li X; Chi Y; Yang J
    Metabolism; 2022 Nov; 136():155292. PubMed ID: 35995281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear lamina genetic variants, including a truncated LAP2, in twins and siblings with nonalcoholic fatty liver disease.
    Brady GF; Kwan R; Ulintz PJ; Nguyen P; Bassirian S; Basrur V; Nesvizhskii AI; Loomba R; Omary MB
    Hepatology; 2018 May; 67(5):1710-1725. PubMed ID: 28902428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioneer Factor Foxa2 Mediates Chromatin Conformation Changes for Activation of Bile Acid Targets of FXR.
    Hao Y; Han L; Wu A; Bochkis IM
    Cell Mol Gastroenterol Hepatol; 2024; 17(2):237-249. PubMed ID: 37879405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel role of CRTC2 in promoting nonalcoholic fatty liver disease.
    Han HS; Kim SG; Kim YS; Jang SH; Kwon Y; Choi D; Huh T; Moon E; Ahn E; Seong JK; Kweon HS; Hwang GS; Lee DH; Cho KW; Koo SH
    Mol Metab; 2022 Jan; 55():101402. PubMed ID: 34838715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuated lipotoxicity and apoptosis is linked to exogenous and endogenous augmenter of liver regeneration by different pathways.
    Weiss TS; Lupke M; Ibrahim S; Buechler C; Lorenz J; Ruemmele P; Hofmann U; Melter M; Dayoub R
    PLoS One; 2017; 12(9):e0184282. PubMed ID: 28877220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
    Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
    J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High fat diet-induced oxidative stress blocks hepatocyte nuclear factor 4α and leads to hepatic steatosis in mice.
    Yu D; Chen G; Pan M; Zhang J; He W; Liu Y; Nian X; Sheng L; Xu B
    J Cell Physiol; 2018 Jun; 233(6):4770-4782. PubMed ID: 29150932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease.
    Kohjima M; Higuchi N; Kato M; Kotoh K; Yoshimoto T; Fujino T; Yada M; Yada R; Harada N; Enjoji M; Takayanagi R; Nakamuta M
    Int J Mol Med; 2008 Apr; 21(4):507-11. PubMed ID: 18360697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MacroH2A1 associates with nuclear lamina and maintains chromatin architecture in mouse liver cells.
    Fu Y; Lv P; Yan G; Fan H; Cheng L; Zhang F; Dang Y; Wu H; Wen B
    Sci Rep; 2015 Nov; 5():17186. PubMed ID: 26603343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of FOXA2 induces ER stress and hepatic steatosis and alters developmental gene expression in human iPSC-derived hepatocytes.
    Aghadi M; Elgendy R; Abdelalim EM
    Cell Death Dis; 2022 Aug; 13(8):713. PubMed ID: 35973994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.
    Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH
    J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation.
    Abdelmoemen G; Khodeir SA; Zaki AN; Kassab M; Abou-Saif S; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2019; 19(2):185-188. PubMed ID: 30009716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
    Liu C; Zhou B; Meng M; Zhao W; Wang D; Yuan Y; Zheng Y; Qiu J; Li Y; Li G; Xiong X; Bian H; Zhang H; Wang H; Ma X; Hu C; Xu L; Lu Y
    J Hepatol; 2021 Jul; 75(1):150-162. PubMed ID: 33548387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes.
    Wang XY; Lu LJ; Li YM; Xu CF
    Life Sci; 2022 Nov; 308():120925. PubMed ID: 36057399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.